Literature DB >> 15798435

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is expressed in normal skin and cutaneous inflammatory diseases, but not in chronically UV-exposed skin and non-melanoma skin cancer.

Sonja Ständer1, Thomas Schwarz.   

Abstract

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a member of the tumor necrosis factor family that preferentially induces apoptosis in transformed but not normal cells and that is constitutively expressed in many organs including the skin. In addition to its therapeutic potential, TRAIL might act as a natural guardian eliminating transformed cells at an early stage. Ultraviolet (UV) radiation is not only a potent carcinogen because of its mutagenic effects but also because of its capacity to paralyze natural protection mechanisms, including the tumor suppressor gene p53. Therefore, we studied the effect of UV exposure on the expression of TRAIL in the skin by immunohistochemical analysis. TRAIL and its receptors TRAIL-R1 and TRAIL-R4 were constitutively expressed in normal epidermis and not altered in a variety of inflammatory dermatoses including those associated with interface dermatitis. TRAIL was not altered in biopsies of acute sunburn, polymorphic light eruption, and photoprovocation testing, indicating that acute UV exposure does not affect TRAIL expression. No differences were observed in UV-protected and chronically UV-exposed skin samples of younger adults. In contrast, TRAIL was significantly reduced in chronically UV-exposed skin of elderly individuals. In addition, TRAIL expression was reduced in actinic keratoses and Bowen disease and almost completely lost in basal cell and squamous cell carcinomas. In contrast, keratoacanthomas did not reveal any alterations in TRAIL expression. Taken together, these data indicate that chronic UV exposure in elderly patients results in the loss of TRAIL expression, which might contribute to the increased risk of skin cancer in this population. Down-regulation of TRAIL might represent another example of a natural protection mechanism that is eliminated by chronic UV exposure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15798435     DOI: 10.1097/01.dad.0000154401.45465.ee

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  7 in total

Review 1.  Keratinocyte apoptosis in epidermal development and disease.

Authors:  Deepak Raj; Douglas E Brash; Douglas Grossman
Journal:  J Invest Dermatol       Date:  2006-02       Impact factor: 8.551

2.  FasL and TRAIL induce epidermal apoptosis and skin ulceration upon exposure to Leishmania major.

Authors:  Liv Eidsmo; Caroline Fluur; Bence Rethi; Sofia Eriksson Ygberg; Nicolas Ruffin; Angelo De Milito; Hannah Akuffo; Francesca Chiodi
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

3.  TRAIL contributes to the apoptotic effect of 13-cis retinoic acid in human sebaceous gland cells.

Authors:  A M Nelson; Z Cong; K L Gilliland; D M Thiboutot
Journal:  Br J Dermatol       Date:  2011-08-17       Impact factor: 9.302

4.  Melatonin maintains mitochondrial membrane potential and attenuates activation of initiator (casp-9) and effector caspases (casp-3/casp-7) and PARP in UVR-exposed HaCaT keratinocytes.

Authors:  T W Fischer; M A Zmijewski; J Wortsman; A Slominski
Journal:  J Pineal Res       Date:  2007-12-13       Impact factor: 13.007

5.  FasL and TRAIL signaling in the skin during cutaneous leishmaniasis - implications for tissue immunopathology and infectious control.

Authors:  Bence Rethi; Liv Eidsmo
Journal:  Front Immunol       Date:  2012-06-19       Impact factor: 7.561

Review 6.  TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications.

Authors:  Paolo Perri; Giorgio Zauli; Arianna Gonelli; Daniela Milani; Claudio Celeghini; Giuseppe Lamberti; Paola Secchiero
Journal:  Biomed Res Int       Date:  2015-03-05       Impact factor: 3.411

7.  Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.

Authors:  Nadarajah Vigneswaran; Darryl C Baucum; Jean Wu; Yahuan Lou; Jerry Bouquot; Susan Muller; Wolfgang Zacharias
Journal:  BMC Cancer       Date:  2007-06-25       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.